Production of insulin-like growth factor-1 in methylotrophic yeast cells
CA 2090969 C · Owner: Merck & Co. Inc. · Inventors: Howard, Bradley D.; Davis, Geneva Ruth; Gleeson, Martin A
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Insulin-like growth factor-1 (IGF-1), a naturally occurring relatively short, single chain polypeptide is prepared by grow-, ing methylotrophic yeast transformants containing in their genome at least one copy of DNA encoding IGF-1, in operational linkage with DNA encoding a signal sequence which is effective for directing , secretion of proteins from the host cells and which also includes the proteolytic processing syte lys-arg and may include one or more glu-ala sequences. In preferred embodiments the signal sequence is the S. cerevisiae alpha mating factor pre-pro sequence. Expression of both the DNA encoding IGF-1 and the pre-pro signal sequence are regulated by a promoter region …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 4, 1991 and granted August 21, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 4, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 4, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.